PDSB
PDS Biotechnology Corp
1.00$
-4.2%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 90.0% | 97.7% | 90.6% | 97.9% | 96.8% | 96.1% | 98.4% | 99.9% | 98.2% | 99.5% | 99.3% | 99.4% | 99.3% | 92.7% | |
| 86.1% | 90.0% | 80.5% | 97.1% | 95.9% | 95.1% | 95.7% | 83.9% | 93.4% | 97.1% | 95.9% | 95.2% | 91.9% | 87.6% | |
| 86.1% | 90.0% | 80.5% | 97.1% | 95.9% | 95.1% | 95.7% | 83.9% | 93.4% | 97.1% | 95.9% | 95.2% | 91.9% | 87.6% | |
| – | 5.3% | – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | – | 2.1% | 0.1% | 0.1% | 0.1% | 0.1% | 1.8% | 0.5% | 0.7% | – | – | – | |
| – | – | – | – | 0.0% | 0.1% | 0.1% | – | – | – | – | – | – | – | |
| 2,166.7% | 275.8% | 263.3% | 8.7% | 19.5% | 32.7% | 17.6% | 19.3% | 12.2% | 5.9% | 42.9% | 56.0% | 58.1% | 69.7% | |
| 2,150.1% | 20.5% | 22.8% | 6.4% | 6.0% | 13.9% | 17.6% | 19.3% | 10.6% | 5.6% | 12.8% | 22.9% | 37.7% | 31.1% | |
| 105.1% | – | 1.6% | -0.2% | 0.0% | 3.3% | – | – | 0.4% | 0.4% | 0.4% | 7.1% | 27.7% | 16.9% | |
| – | 12.4% | 12.0% | 1.9% | 3.1% | 4.7% | 1.1% | 8.3% | 4.6% | 1.9% | 1.6% | 11.8% | 3.7% | 11.7% | |
| – | – | – | 2.3% | 13.5% | 18.8% | 0.1% | – | – | – | 29.9% | 32.8% | 20.3% | 38.5% | |
| -2,066.7% | -175.8% | -163.3% | 91.3% | 80.5% | 67.3% | 82.4% | 80.7% | 87.8% | 94.1% | 57.1% | 44.0% | 41.9% | 30.3% | |
| -4,932.6% | -183.6% | -174.9% | -46.4% | -91.1% | -164.1% | -532.3% | -199.7% | -141.7% | -90.3% | -131.9% | -243.3% | -401.5% | -710.3% | |
| 461.3% | 8.6% | 4.4% | 1.0% | 1.3% | 1.6% | 11.0% | 33.6% | 54.2% | 38.1% | 37.1% | 52.1% | 80.4% | 152.1% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.